Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy

Anlotinib is a new multitarget tyrosine kinase inhibitor for tumor angiogenesis, and its monotherapy exhibits a decent clinical efficacy. However, the process of combining Anlotinib and immune checkpoint therapy to achieve optimal antitumor effects while limiting side effects remains unclear. In thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Peng, Qiang, Huiping, Liu, Zhenhua, Zhao, Qi, Wang, Ying, Liu, Tingkun, Wang, Xuan, Chu, Tianqing, Huang, Yuhui, Xu, Wei, Qin, Songbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382125/
https://www.ncbi.nlm.nih.gov/pubmed/35990640
http://dx.doi.org/10.3389/fimmu.2022.937924

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382125/
https://www.ncbi.nlm.nih.gov/pubmed/35990640
http://dx.doi.org/10.3389/fimmu.2022.937924

Ejemplares similares